ars-pharma.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $76.55MM
ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/31/2021 | Series D | $55MM | $xx.xx | $310.11MM | Deerfield, Ra Capital Management, Sr One | |
Price per Share
$xx.xx
Shares Outstanding
9,337,066
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deerfield, Ra Capital Management, Sr One
|
||||||
09/14/2018 | Series C | $20.15MM | $xx.xx | $113.71MM | Deerfield Management | |
Price per Share
$xx.xx
Shares Outstanding
7,749,999
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deerfield Management
|
||||||
04/30/2018 | Series B | $999,999.00 | $xx.xx | $44.3MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
606,060
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
04/30/2016 | Series A | $396,841.00 | $xx.xx | $1.13MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,764,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|